Health Catalyst (NASDAQ:HCAT) Stock Price Down 3.2% After Analyst Downgrade

Health Catalyst, Inc. (NASDAQ:HCATGet Rating)’s stock price fell 3.2% during mid-day trading on Wednesday after BTIG Research lowered their price target on the stock from $35.00 to $25.00. The company traded as low as $15.20 and last traded at $15.20. 9,981 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 649,629 shares. The stock had previously closed at $15.70.

A number of other research analysts have also recently issued reports on the company. Royal Bank of Canada decreased their target price on Health Catalyst from $35.00 to $19.00 in a research note on Wednesday, May 11th. Canaccord Genuity Group decreased their target price on Health Catalyst from $35.00 to $17.00 in a research note on Wednesday, May 11th. Piper Sandler decreased their target price on Health Catalyst from $38.00 to $21.00 in a research note on Wednesday, May 11th. The Goldman Sachs Group cut their price target on Health Catalyst from $42.00 to $37.00 and set a “buy” rating on the stock in a report on Thursday, May 26th. Finally, Guggenheim initiated coverage on Health Catalyst in a report on Wednesday, April 13th. They issued a “buy” rating and a $39.00 price target on the stock. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $33.17.

Insider Activity at Health Catalyst

In related news, insider Linda Llewelyn sold 1,860 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $15.87, for a total value of $29,518.20. Following the completion of the transaction, the insider now directly owns 60,173 shares of the company’s stock, valued at $954,945.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Health Catalyst news, insider Linda Llewelyn sold 1,860 shares of Health Catalyst stock in a transaction on Monday, May 16th. The shares were sold at an average price of $15.87, for a total transaction of $29,518.20. Following the completion of the transaction, the insider now directly owns 60,173 shares of the company’s stock, valued at $954,945.51. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Daniel H. Orenstein sold 2,838 shares of Health Catalyst stock in a transaction on Monday, June 6th. The stock was sold at an average price of $14.85, for a total transaction of $42,144.30. Following the transaction, the general counsel now directly owns 103,671 shares of the company’s stock, valued at $1,539,514.35. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,255 shares of company stock valued at $93,877. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. Fairfield Bush & CO. acquired a new stake in shares of Health Catalyst during the first quarter worth $25,000. UMB Bank N A MO acquired a new stake in shares of Health Catalyst during the fourth quarter worth $30,000. Manchester Capital Management LLC lifted its holdings in shares of Health Catalyst by 667.5% during the first quarter. Manchester Capital Management LLC now owns 1,159 shares of the company’s stock worth $30,000 after buying an additional 1,008 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Health Catalyst during the first quarter worth $33,000. Finally, Sageworth Trust Co of South Dakota acquired a new stake in shares of Health Catalyst during the fourth quarter worth $61,000. Institutional investors and hedge funds own 97.53% of the company’s stock.

Health Catalyst Stock Up 3.8 %

The company has a market cap of $894.59 million, a price-to-earnings ratio of -5.33 and a beta of 1.07. The stock has a fifty day moving average price of $14.98 and a two-hundred day moving average price of $21.22.

Health Catalyst (NASDAQ:HCATGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. The business had revenue of $68.09 million during the quarter, compared to the consensus estimate of $66.01 million. Health Catalyst had a negative return on equity of 19.88% and a negative net margin of 57.95%. Health Catalyst’s revenue for the quarter was up 21.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. Analysts predict that Health Catalyst, Inc. will post -1.83 earnings per share for the current fiscal year.

About Health Catalyst

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Read More

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.